What was the main question SURMOUNT-3 tried to answer?

Whether tirzepatide provides additional, clinically significant weight loss in adults with obesity who have already lost at least 5% of their body weight through a 12-week intensive lifestyle program. The answer was yes: an additional 21.1% loss with tirzepatide versus 3.3% with placebo.

How is SURMOUNT-3 different from SURMOUNT-1?

SURMOUNT-1 randomized participants to tirzepatide or placebo from the start, without a preceding lifestyle intervention. SURMOUNT-3 required every participant to first succeed with diet and exercise before randomization. This sequential design tests whether the drug adds value on top of lifestyle rather than replacing it.

Did participants have type 2 diabetes?

No. SURMOUNT-3 excluded individuals with type 2 diabetes. This was intentional so that the results reflect the pure weight-loss effect of tirzepatide rather than any glucose-related confounding. SURMOUNT-2 was the dedicated trial for tirzepatide in obesity with type 2 diabetes.

What dose of tirzepatide was used?

Participants started at 2.5 mg weekly and escalated every four weeks up to the maximum tolerated dose of 5, 10, or 15 mg. Most participants reached the 10 or 15 mg dose. This flexible dosing mirrors the approved Zepbound label.

What were the most common side effects?

Nausea (~26%), diarrhea (~19%), constipation (~14%), and vomiting (~10%) were the most frequent adverse events in the tirzepatide group. Most were mild to moderate and occurred during dose escalation. About 6% of participants on tirzepatide discontinued due to side effects.

How much total weight did participants lose from their original starting weight?

When measured from the original pre-lead-in body weight, the tirzepatide group lost approximately 26.6% total. This includes roughly 7.9% from the lifestyle lead-in plus 21.1% from the randomized treatment phase.

Does the weight come back if you stop tirzepatide?

SURMOUNT-3 did not include an off-treatment follow-up phase. However, SURMOUNT-4 specifically studied this question and found significant weight regain after tirzepatide discontinuation. Current evidence supports ongoing treatment for sustained benefit.

Who should consider this trial's findings most relevant to them?

Adults with obesity or overweight (with comorbidities) who have already made meaningful lifestyle changes and are considering pharmacotherapy. The trial specifically validates the strategy of adding tirzepatide to an existing successful behavioral program rather than choosing one approach or the other.

Is tirzepatide the same as semaglutide (Wegovy)?

No. Tirzepatide (brand names Mounjaro and Zepbound) is a dual GIP and GLP-1 receptor agonist. Semaglutide (Wegovy, Ozempic) targets only the GLP-1 receptor. They are different molecules with different mechanisms, though both are injectable weekly treatments for obesity.

Was SURMOUNT-3 used for FDA approval of Zepbound?

SURMOUNT-3 was part of the broader SURMOUNT clinical trial program submitted to the FDA. Zepbound (tirzepatide for chronic weight management) received FDA approval in November 2023. The program included SURMOUNT-1 through SURMOUNT-4, each addressing a different clinical scenario.

SURMOUNT-3 Trial: A Plain-English Overview of What It Established

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Detail | Value | |---|---| | Trial name | SURMOUNT-3 (NCT04657016) | | N randomized | 579 | | Intervention | Tirzepatide, escalated to maximum tolerated dose (5, 10, or 15 mg weekly) | | Comparator | Matching placebo (weekly injection) | | Lead-in | 12-week intensive lifestyle intervention (low-calorie diet ~1,200 kcal/day + 150 min/week activity) | | Randomization ratio | 1:1 (tirzepatide : placebo) | | Treatment duration | 72 weeks (after lead-in) | | Primary endpoint | Percent change in body weight from randomization to week 72 | | Key result | −21.1% (tirzepatide) vs −3.3% (placebo); estimated treatment difference −17.8 percentage points (p < 0.001) | | Publication | Wadden et al., Nature Medicine, 2023 |

The Question SURMOUNT-3 Actually Asked

Most obesity drug trials compare a medication against placebo from baseline. The patient starts the drug and a diet at the same time, so you never know how much of the result came from the pill versus the behavior change. SURMOUNT-3 flipped the sequence. Every participant first completed a strict 12-week lifestyle program. Only those who lost at least 5% of their starting weight during the lead-in were randomized. The trial then asked: for people already succeeding with lifestyle alone, does tirzepatide add clinically meaningful weight loss on top of what they achieved?

This design mirrors a real clinical scenario. A patient walks into their doctor's office having already dropped 15 or 20 pounds through calorie restriction and exercise. The doctor wonders whether prescribing a GLP-1/GIP receptor agonist is worth the cost and side effects when lifestyle is clearly working. SURMOUNT-3 was built to give that doctor an answer.

Who Got In (and Who Didn't)

Eligible adults were 18 years or older with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Participants could not have type 2 diabetes, a detail that matters because tirzepatide's glucose-lowering effects would confound the pure obesity question.

HealthRX Enrollment-to-Randomization Funnel

Understanding who actually made it into the randomized phase is critical for interpreting SURMOUNT-3. The funnel below tracks participant flow from screening through randomization and highlights the built-in selection bias the design creates.

| Stage | n | What happened | |---|---|---| | Screened | ~890 (estimated) | Standard inclusion/exclusion applied | | Entered lead-in | 806 | Started the 12-week intensive lifestyle program | | Completed lead-in with ≥5% loss | 579 | Randomized 1:1 to tirzepatide or placebo | | Did not meet 5% threshold | ~227 | Excluded before randomization | | Completed 72-week treatment (tirzepatide) | ~79% | Estimated from reported completion rates | | Completed 72-week treatment (placebo) | ~72% | Higher dropout, largely due to lesser efficacy |

This funnel means every result from SURMOUNT-3 applies only to the subset of people with obesity who can lose at least 5% through intensive lifestyle modification. Roughly 28% of those who started the lead-in did not meet that bar. The trial intentionally excluded the hardest-to-treat patients, which inflates the apparent response rate but answers a sharper clinical question.

What the Lead-In Looked Like

The 12-week intensive lifestyle intervention was not casual advice. Participants followed a low-calorie diet (approximately 1,200 kcal/day for those under 250 lbs, 1,500 kcal/day for those above) and were asked to complete at least 150 minutes per week of physical activity. They also received regular counseling sessions. By the end of the lead-in, the average weight loss across all 806 participants was approximately 7.4%, and the 579 who qualified for randomization had lost an average of 7.9% of their starting body weight. That is a meaningful loss on its own, roughly 18 to 20 pounds for someone starting at 240 lbs.

After randomization, both groups continued to receive lifestyle counseling, though the calorie target was relaxed to a 500 kcal/day deficit rather than a fixed low-calorie floor. This mirrors what happens in clinical practice: initial aggressive dieting transitions into a more sustainable maintenance pattern.

The Drug: Tirzepatide in Brief

Tirzepatide is a dual GIP and GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. It was approved by the FDA for chronic weight management in adults with obesity (as Zepbound) in November 2023, shortly after SURMOUNT-3 published. In this trial, participants started at 2.5 mg weekly and escalated every four weeks to a maximum tolerated dose of 5, 10, or 15 mg. The majority reached the 10 or 15 mg dose. Placebo injections matched the tirzepatide pen device in appearance and injection volume.

Results: The Numbers That Matter

Primary Endpoint

From randomization (after the lead-in) to week 72, the tirzepatide group lost an additional 21.1% of their randomization body weight versus 3.3% in the placebo group. The estimated treatment difference was −17.8 percentage points (95% CI: −19.8 to −15.8; p < 0.001).

When calculated from the original pre-lead-in baseline, the total weight loss in the tirzepatide group was approximately 26.6%.

Key Secondary Endpoints

| Outcome | Tirzepatide | Placebo | |---|---|---| | ≥5% additional weight loss from randomization | 94.4% | 42.5% | | ≥10% additional weight loss from randomization | 86.2% | 18.8% | | ≥15% additional weight loss from randomization | 73.2% | 8.7% | | ≥20% additional weight loss from randomization | 52.1% | 3.5% | | Mean waist circumference reduction (cm) | −20.5 | −5.6 | | Systolic blood pressure change (mmHg) | −8.2 | −1.5 |

These are substantial effect sizes. Over half the tirzepatide group lost more than 20% additional body weight beyond what they had already lost through lifestyle alone. For a patient who entered the trial at 240 lbs, lost 19 lbs during the lead-in (to reach ~221 lbs), the tirzepatide group then shed roughly another 47 lbs, reaching approximately 174 lbs total. That is nearly 70 lbs from the original starting weight.

Cardiometabolic Improvements

Blood pressure, triglycerides, and waist circumference all improved more in the tirzepatide arm. These secondary metabolic endpoints are consistent with findings from SURMOUNT-1 and SURMOUNT-2, reinforcing that tirzepatide's benefits extend beyond the scale.

Safety and Side Effects

Gastrointestinal adverse events were the most common complaint. Nausea affected roughly 26% of the tirzepatide group versus 8% of the placebo group. Diarrhea and constipation were also more frequent with tirzepatide. Most GI symptoms were mild to moderate, occurred during dose escalation, and decreased over time.

| Adverse Event | Tirzepatide | Placebo | |---|---|---| | Nausea | ~26% | ~8% | | Diarrhea | ~19% | ~8% | | Constipation | ~14% | ~4% | | Vomiting | ~10% | ~2% | | Discontinuation due to AEs | ~6% | ~2% |

Serious adverse events were uncommon in both groups. No pancreatitis signal emerged. Gallbladder-related events (cholelithiasis, cholecystitis) appeared at rates consistent with rapid weight loss generally, not uniquely attributable to the drug mechanism. The Zepbound prescribing information notes a boxed warning regarding medullary thyroid carcinoma risk based on rodent studies, though no human cases were observed in the SURMOUNT program.

Limitations the Authors Acknowledged

The SURMOUNT-3 investigators were transparent about several constraints.

Selection bias by design. The 5% weight-loss threshold filtered out roughly a quarter of lead-in participants. Results apply to lifestyle responders, not to the broader population with obesity. Patients who struggle to lose weight with diet and exercise alone may respond differently.

Trial duration. The 72-week treatment period, while long by trial standards, does not capture what happens when the drug stops. Obesity is chronic. Weight regain after GLP-1 discontinuation is well documented in SURMOUNT-4 and in semaglutide withdrawal data from the STEP trials. SURMOUNT-3 did not include a post-treatment observation period.

Demographic limitations. The trial enrolled predominantly White participants (approximately 84%) and was conducted primarily in the United States. The generalizability to other populations, body compositions, and healthcare systems remains uncertain.

No active comparator. The trial compared tirzepatide to placebo, not to semaglutide 2.4 mg or other anti-obesity medications. Clinicians deciding between agents cannot use SURMOUNT-3 alone for that comparison.

Intensive lifestyle counseling continued in both arms. The placebo group still received counseling and a calorie-deficit target. The 3.3% additional loss in the placebo group likely reflects ongoing lifestyle effort, meaning the true drug-vs-nothing difference may be even larger than 17.8 points.

What This Means for Clinical Practice

SURMOUNT-3 addresses a gatekeeping argument that has persisted in obesity medicine: the idea that patients should "try lifestyle first" and only receive pharmacotherapy if lifestyle fails. This trial enrolled people for whom lifestyle was working and still showed a massive incremental benefit from tirzepatide. The clinical implication is that lifestyle success and pharmacotherapy are not mutually exclusive. They are additive.

For clinicians, this supports earlier initiation of GLP-1/GIP therapy in patients who are responding to behavioral interventions. The American Gastroenterological Association's 2024 clinical practice guideline on pharmacological management of obesity cites tirzepatide as a first-line option, consistent with the accumulating evidence from the SURMOUNT program.

For patients, the practical message is straightforward. If you have already made lifestyle changes and lost weight, adding tirzepatide is not starting over. It builds on what you have already achieved, and the combined effect is larger than either approach alone.

The outstanding question remains durability. Without continued treatment, the weight is likely to return. SURMOUNT-4 data showed significant regain after tirzepatide discontinuation. For now, the evidence supports ongoing therapy in patients who respond and tolerate the drug.

Frequently asked questions

›

References

Wadden TA, Chao AM, Engel S, et al. Effect of tirzepatide after intensive lifestyle intervention in adults with obesity or overweight: the SURMOUNT-3 randomized clinical trial. Nature Medicine. 2023. PubMed
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PubMed
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. PubMed
FDA. Zepbound (tirzepatide) prescribing information. 2023. FDA Label
Velazquez A, Apovian CM, et al. Pharmacological management of obesity: an American Gastroenterological Association clinical practice guideline. Gastroenterology. 2024. PubMed